CTR20262487 IMD-1828 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262487 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262487 is a hot trial to watch
Advanced Malignant Solid Neoplasm is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262487 is notable because it evaluates IMD-1828 in a Phase 1/2 design sponsored by Shanghai Yingmaide Medical Technology Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262487 |
| Official title | 一项评估IMD1828在晚期实体瘤参与者中的安全性、耐受性、药代动力学、免疫原性和初步有效性的多中心、开放性、剂量递增和剂量扩展的I/II期全球研究 |
| Phase / status | Phase 1/2 / 进行中 （招募中） |
| Intervention | IMD-1828 |
| Sponsor | Shanghai Yingmaide Medical Technology Co., Ltd. |
| Geography | China |
| Enrollment | [object Object],[object Object] |
| Primary endpoint | |
| Endpoint time frame | Ⅰa期剂量递增阶段 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 1/2 study of IMD-1828 in Advanced Malignant Solid Neoplasm.
Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of [object Object],[object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (Ⅰa期剂量递增阶段) — 不良事件（AEs）和严重不良事件（SAEs）的发生率及严重程度。
- Primary endpoint (Ⅰa期剂量递增阶段) — 剂量限制性毒性（DLTs）的发生率。
- Primary endpoint (Ⅰa期剂量递增阶段) — 确定MTD和/或RDE。
- Primary endpoint (Ib期剂量扩展阶段和II期剂量优化阶段) — AEs和SAEs的发生率及严重程度
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: IMD-1828 is indexed as Antibody drug conjugate (ADC), with target CLDN6 x Top I, mechanism CLDN6 inhibitors, TOP1 inhibitors, and global highest development status Phase 1/2.
Company & Deal Intelligence MCP profile: Shanghai Yingmaide Medical Technology Co., Ltd. is resolved to a normalized organization record in Shanghai Shi, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262487 provides a focused lens on Advanced Malignant Solid Neoplasm development. Its value will be determined by whether IMD-1828 can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
